Luminex Testing Options: **SARS-CoV-2**

SARS-CoV-2 Targeted Detection Assays

MODERATE COMPLEXITY: SAMPLE-TO-ANSWER

ARIES®

SARS-CoV-2 Assay (EUA)

- **50-10047**
  - 24 tests/kit
  - Sample type: NPS in UTM*
  - Up to 12 samples per run
  - TAT: ~2 hours
  - LoD: 333 copies/mL
  - Ship: 4°C
  - Store: -15–25°C
  - Gene targets: ORF1ab and N

ARIES® Workflow



Step 1
Load the sample into the cassette.

Step 2
Insert up to six cassettes into the magazine.

Step 3
Insert one or both magazines into the instrument.

Step 4
Review & release results.

Respiratory Panels That Detect SARS-CoV-2

HIGH COMPLEXITY: HIGH-THROUGHPUT

NxTAG®

CoV Extended Panel (EUA)

- **I054C0463**
  - 96 tests/kit
  - Sample type: NPS in UTM*
  - Up to 96 samples per run
  - TAT: ~4 hours (including extraction)
  - LoD: 5,000 copies/mL
  - Ship: 2-30° C
  - Store:
    - Plates 2–8°C
    - MS2 -25-8°C
    - Foil seals 15-30°
  - Gene targets: ORF1ab, N, and E

NxTAG® Workflow (Post-Extraction)

Step 1
Add 1-96 extracted samples to pre-plated test wells.

Step 2
Integrated multiplex PCR and bead hybridization.

Step 3
Read on the MAGPIX® System.

NxTAG®

RPP + SARS-CoV-2 (EUA)

- **I056C0468**
  - 19 viral pathogens, including SARS-CoV-2
  - 2 bacterial pathogens
  - 96 tests/kit
  - Sample type: Nasopharyngeal swabs
  - Up to 96 samples per run
  - TAT: ~4 hours (including extraction)
  - LoD (SARS-CoV-2): 500 copies/mL
  - Ship: 2-30° C
  - Store:
    - Plates 2–8°C
    - MS2 -25-8°C
    - Foil seals 15-30°
  - Gene targets (SARS-CoV-2): ORF1ab and M

NxTAG® Workflow (Post-Extraction)

Step 1
Add 1-96 extracted samples to pre-plated test wells.

Step 2
Integrated multiplex PCR and bead hybridization.

Step 3
Read on the MAGPIX® System.

**In UTM or equivalent. For the ARIES® Assay, the use of Amies transport medium or PBS is not recommended.*

Gene targets for the detection of the SARS-CoV-2 virus vary by assay to ensure optimal multiplex product performance and may aid in Luminex's ability to support SARS-CoV-2 testing in the event of future viral genetic drift.

Luminex®
complexity simplified.

For more information, please visit luminexcorp.com/covid19-testing-solutions

The NxTAG CoV Extended Panel and the ARIES® SARS-CoV-2 Assay have each been funded with $642,450 of Federal funds, approximately 36% each of the expected overall cost of development, from the Department of Health and Human Services; Office of the Assistant Secretary for Preparedness and Response; Biomedical Advanced Research and Development Authority, Division of Research Innovation and Ventures under Contract Nos. 75A50120C00037 (NxTAG CoV Extended Panel) and 75A50120C00043 (ARIES® SARS-CoV-2 Assay). Luminex financed the remaining $1,118,663 of each program, constituting 64% each of the total program costs.